Drug Profile
CT 400
Alternative Names: CT-400Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator CisThera
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Sep 2023 CT 400 is still in preclinical trials for Cancer in the US (CisThera pipeline, September 2023)
- 06 Sep 2023 CisThera plans a clinical trial for Cancer (CisThera pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA